Jeffrey West

25PUBLICATIONS
81CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|May 22, 2026
Evolutionary antifragile therapy is a treatment strategy to suppress drug resistance by exploiting dose response convexity.

|Mar 27, 2026
A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind.

Rena Emond, Jeffrey West, Vince K Grolmusz

|Feb 16, 2026
Modeling the evolutionary dynamics of clonal hematopoiesis.

Sadegh Marzban, Thomas Stiehl, Zhuoer Xie

|Nov 26, 2025
Cell State Transitions Drive the Evolution of Disease Progression in B-Lymphoblastic Leukemia.

Curtis Gravenmier, Sadegh Marzban, Yi-Han Tang

|Oct 17, 2025
Mathematical Oncology: How Modeling Is Transforming Clinical Decision-Making.

Kevin R Scibilia, Kit Gallagher, M A Masud

|Sep 26, 2025
Evolutionary antifragile therapy.

Jeffrey West, Bina Desai, Maximilian Strobl

Pageof 5

Frequent Collaborators

17 joint publications

Alexander R A Anderson

7 joint publications

Jill Gallaher

6 joint publications

Maximilian Strobl

6 joint publications

Mark Robertson-Tessi